跳至主要内容
临床试验/TCTR20190103001
TCTR20190103001尚未招募未知

euro-immune, neuro-oxidative and neuro-nitrosative pathways in association with LINE1/Alu methylation in acute schizophrenia

the Ratchadapisek Somphot Fund0 个研究点目标入组 90 人开始时间: 2019年1月3日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • 1.An acute phase of schizophrenia (both new onset schizophrenia patients and patients with acute exacerbations) while being able to cooperate with the study protocol (therefore a window of 10 days from admission is allowed). Thus we will include patients in an acute state with positive symptom exacerbations or psychotic decompensation or disorganization.
  • 2.Meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text-Revised and DSM-5 criteria for schizophrenia.

排除标准

  • 1.A current and life-time diagnosis of axis-I DSM IV-TR / DSM-5 disorders other than schizophrenia, e.g. major depression or bipolar disorder, substance use disorders, psycho-organic disorders, etc.
  • Exclusion criteria for patients and controls are:
  • 1.Medical illnesses, such as inflammatory bowel disease and rheumatoid arthritis; COPD; neurodegenerative disorders; diabetes type 1 and 2, dementia, Parkinson’s and Huntington’s disease, stroke, etc.
  • 2.Treatments with immunomodulatory drugs, including glucocorticoids; and c) alcohol abuse.

研究者

发起方
the Ratchadapisek Somphot Fund

相似试验